KRAS and colorectal carcinoma: The MT-sDNA test, ColoGuard, combining stool DNA markers (methylated BMP3 and NDRG4 promoter regions, mutant KRAS) with the results of FIT, undoubtedly represented a milestone of stool-based molecular testing in CRC screening.